The association of lowered efavirenz dosage and reduction in LDL and total cholesterol, makes it a possible approach for treatment of patients with metabolic or cardiovascular comorbidities.
Increasing the length of nightly sleep may help reduce the risk for cardiovascular disease and metabolic disorders.
In FCS, mutations in lipoprotein lipase lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.
Livalo is indicated for pediatric patients ≥8 years old with HeFH to reduce TC, LDL-C, and Apo-B.
PCSK9 inhibition with evolocumab was safe and more effective than statin monotherapy in reducing LDL-C in stable individuals with moderate CKD and clinically evident atherosclerosis.
Considering more individuals are eligible for statin therapy based on 2018 cholesterol guidelines, it is important to examine the possibility that the medication may impair gonadal steroidogenesis.
Investigators examined how genetic factors associated with cardiovascular and non-cardiovascular diseases may have an effect on reported comorbid conditions.
In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…
For Chinese postmenopausal women, vitamin D (VitD) and estradiol (E2) deficiency have a synergistic effect on metabolic syndrome.
Variability in sleep duration and timing is associated with higher odds of metabolic syndrome.
